Finance

Lists
Outlook: 81.8% bullish·9.1% bearish
Go to analysis
MAZE:NASDAQ
Maze Therapeutics Inc
$36.09
-1.74%
(-0.64) 1D
$36.61
+1.44% (+0.52)
After hours
Closed: Nov 12, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MAZE...
Open
$36.29
High
$36.94
Low
$35.31
Mkt. cap
1.97B
Avg. vol.
718.69K
Volume
0.00
52-wk high
$53.65
52-wk low
$21.95
EPS
-$2.64
Shares outstanding
54.68M
No. of employees
141
Open
$36.29
High
$36.94
Low
$35.31
Mkt. cap
1.97B
Avg. vol.
718.69K
Volume
0.00
52-wk high
$53.65
52-wk low
$21.95
EPS
-$2.64
Shares outstanding
54.68M
No. of employees
141
News stories
From web sources and news partners
About Maze Therapeutics Inc
CEO-
Employees141
Founded2017
HeadquartersSouth San Francisco, California, United States
SectorHealth Care
IndustryPharmaceutical industry
Websitemazetx.com
Analyst ratings
Based on 10 analysts giving stock ratings to MAZE in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for MAZE in the last 3 months.
Highest
Current $36.09
$110.00 (+204.79%)
Average
$60.60 (+67.91%)
Lowest
$46.00 (+27.46%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ananda Ghosh
H.C. Wainwright
Buy
Maintained
$110.00
+204.8%
11/10/2026
Anupam Rama
J.P. Morgan
Buy
Reiterated
$51.00
+41.3%
11/11/2026
Whitney Ijem
Canaccord Genuity
Buy
Maintained
$75.00
+107.8%
11/10/2026
Sadia Rahman
Wells Fargo
Buy
Reiterated
$55.00
+52.4%
11/10/2026
Julian Harrison
BTIG
Buy
Maintained
$46.00
+27.5%
11/09/2026
Eric Joseph
Citi
Buy
Maintained
$50.00
+38.5%
11/09/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
$50.00
+38.5%
10/29/2026
Laura Chico
Wedbush
Buy
Maintained
$48.00
+33%
09/23/2026
Rami Katkhuda
LifeSci Capital
Buy
Maintained
$57.00
+57.9%
09/22/2026
Danielle Brill
Truist Financial
Buy
Maintained
$64.00
+77.3%
09/22/2026
Salim Syed
Mizuho Securities
Buy
Maintained
$97.00
+168.8%
06/23/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/12/2026
Martin Auster
Raymond James
Buy
Reiterated
$56.00
+55.2%
03/25/2026
Joseph Schwartz
Leerink Partners
Buy
Reiterated
$50.00
+38.5%
03/25/2026
Debjit Chattopadhyay
Guggenheim
Buy
Reiterated
$58.00
+60.7%
03/04/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
20.00M
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
27.57M
34.15M
34.94M
40.22M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.49M
12.40M
13.10M
11.30M
Operating expense
38.06M
46.55M
48.04M
51.52M
Total operating expenses
38.06M
46.55M
48.04M
51.52M
Operating income
-38.06M
-26.55M
-48.04M
-51.52M
Other non operating income
-
-
-
-
EBT including unusual items
-34.57M
-24.21M
-44.73M
-47.97M
EBT excluding unusual items
-34.57M
-24.21M
-44.73M
-47.97M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-34.57M
-24.21M
-44.73M
-47.97M
Net profit margin
-
-121.04%
-
-
Earnings per share
-0.65
-0.45
-0.76
-0.79
Interest and investment income
3.49M
3.21M
4.24M
4.52M
Interest expense
-
-866.00K
-931.00K
-975.00K
Net interest expenses
3.49M
2.34M
3.31M
3.55M
Depreciation and amortization charges
-
-
-
-
EBITDA
-37.56M
-26.11M
-47.64M
-51.13M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps